Fellowship · Chapel Hill, NC
Sponsored by University of North Carolina Hospitals
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.
American journal of respiratory and critical care medicine · 2023 · 128 citations · Jennifer Goralski
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
The Lancet. Respiratory medicine · 2023 · 109 citations · George Retsch-Bogart
Primary Ciliary Dyskinesia: A Clinical Review.
Cells · 2024 · 82 citations · Alex Despotes, Stephanie Davis, Thomas Ferkol
European Respiratory Society and American Thoracic Society guidelines for the diagnosis of primary ciliary dyskinesia.
The European respiratory journal · 2025 · 41 citations · Stephanie Davis, Thomas Ferkol
The E-cigarette or Vaping Product Use-Associated Lung Injury Epidemic: Pathogenesis, Management, and Future Directions: An Official American Thoracic Society Workshop Report.
Annals of the American Thoracic Society · 2023 · 90 citations ·
Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023 · 116 citations · Michael Schechter
Advances and prospects for the Human BioMolecular Atlas Program (HuBMAP).
Nature cell biology · 2023 · 157 citations · James Hagood
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.
American journal of respiratory and critical care medicine · 2023 · 63 citations · George Retsch-Bogart